| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4196595 | Biomedical and Environmental Sciences | 2008 | 6 Pages |
ObjectiveTo filtrate breast cancer resistance protein (BCRP)-mediated resistant agents and to investigate clinical relationship between bcrp expression and drug resistance.MethodsMTT assay was performed to filtrate BCRP-mediated resistant agents with bcrp expression cell model and to detect chemosensitivity of breast cancer tissue specimens to these agents. a high performance liquid chromatography (hplc) assay was established, and was used to measure the relative dose of intracellular retention resistant agents. rt-pcr and immunohistochemistry (ihc) were employed to investigate the bcrp expression in breast cancer tissue specimens.ResultsMTT assay showed that the expression of bcrp increased with the increasing resistance of 5-fluorouracil (5-Fu) (P<0.05, n=3) in the cell model, while hplc assay indicated that the intracellular retention dose of 5-Fu was significantly correlated with the expression of bcrp (r=-0.897, P<0.05, n=3). a total of 140 breast cancer tissue specimens were collected. BCRP-positive expression was detected in forty-seven specimens by both rt-pcr and ihc. As shown by mtt assay subsequently, the resistance index (ri) of 47 BCRP-positive breast cancer tissue specimens to 5-Fu was 7-12 times as high as that of adjacent normal tissue samples. bcrp expression was related to 5-Fu resistance (r2=0.8124, P<0.01).ConclusionResistance to 5-Fu can be mediated by bcrp. Clinical chemotherapy for breast cancer patients can be optimized based on BCRP-positive expression.
